CCO Oncology Podcast
Een podcast door Clinical Care Options
189 Afleveringen
-
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC
Gepubliceerd: 25-3-2025 -
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer
Gepubliceerd: 20-2-2025 -
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
Gepubliceerd: 10-2-2025 -
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer
Gepubliceerd: 9-1-2025 -
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
Gepubliceerd: 22-10-2024 -
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations
Gepubliceerd: 16-10-2024 -
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Gepubliceerd: 1-10-2024 -
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
Gepubliceerd: 30-9-2024 -
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC
Gepubliceerd: 6-9-2024 -
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
Gepubliceerd: 5-9-2024 -
ROS1-Alterations and Molecular Testing in Advanced NSCLC
Gepubliceerd: 28-8-2024 -
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Gepubliceerd: 5-8-2024 -
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Gepubliceerd: 22-7-2024 -
Current Clinical Practice and NCCN Guidelines for CLL/SLL
Gepubliceerd: 18-7-2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
Gepubliceerd: 12-7-2024 -
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
Gepubliceerd: 11-7-2024 -
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Gepubliceerd: 9-7-2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for AML
Gepubliceerd: 8-7-2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
Gepubliceerd: 5-7-2024 -
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
Gepubliceerd: 14-5-2024
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
